44 results about "CDKN2A" patented technology

The invention relates to tumor susceptibility 62 genes and application thereof. The tumor susceptibility 62 genes comprise PTEN, STK11, CDH1, TP53, BRCA1, BRCA2, PALB2, CHEK2, ATM, BRIP1, NBN, RAD51C, MLH1, MSH2, MSH6, PMS2, BARD1, RAD51D, MRE11A, MUTYH, PMS1, RAD50, XRCC2, AKT1, PIK3CA, FANCC, RECQL, CCND1, ERBB2, ESR1, GATA3, FGFR1, MAP2K4, MAP3K1, BAI3, CTNNB1, BRAF, KRAS, CTNNA1, EPCAM, APC, BLM, SMAD4, BMPR1A, POLD1, POLE, AXIN2, MEN1, KIT, EGFR, EZH2, PRF1, CDKN2A, CDK4, BAP1, RB1, ERCC2, VHL, MET, FH, FLCN and RET. The detection of the genes can be used for evaluating tumor susceptibility.

The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans.

The invention relates to a kit for detecting susceptibility gene SNP locus of nasopharynx cancer, which is realized through the steps as follows: detecting a PCR amplimer and a single-base extension primer of an SNP locus rs2860580 of a susceptibility gene CDKN2A-CDKN2B of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs1572072 and rs9510787 of a susceptibility gene TNFRSF19 area of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs28421666,rs2860580 and rs2894207 of a susceptibility gene HLA of nasopharynx cancer; and detecting a PCR amplimer and a single-base extension primer of an SNP locus rs6774494 of a susceptibility gene MDS1-EVI1 of nasopharynx cancer. The kit provided by the invention can be used for simultaneously detecting the SNP loci of a plurality of susceptibility genes of nasopharynx cancer, and provides reference for estimating risk degree of individuals affected by nasopharynx cancer, general survey of populations with high nasopharynx cancer incidence, screening of high risk group attacked by nasopharynx cancer and implementation of relative precautionary measures.

The invention discloses cell-in-cell (CIC) cell models targeting to CDKN2A and preparation methods of the cell-in-cell (CIC) cell models. For the methods for preparing the cell-in-cell relevant cell models provided by the invention, the cell-in-cell relevant cell models are prepared by regulating the expression of the CDKN2A gene in the target cell. An inducing cell-in-cell cell model can be prepared by inhibiting the expression of the CDKN2A gene in the target cell, and an inhibiting cell-in-cell cell model can be prepared by realizing overexpression of the CDKN2A gene in the target cell. Forthe method for promoting the formation of the CIC structure by interfering the expression of the CDKN2A gene provided by the invention, the complete tumor cell is expressed aiming at CDKN2A, throughthe method, the intracellular death mediated by CIC can be promoted, and the purposes of killing tumor cells and inhibiting tumor growth can be realized.

The present invention provides a diabetes type II gene susceptivity and pre-warning detection kit, which is characterized in that seven nucleic acid (DNA and RNA) molecule markers are combined, wherein the seven nucleic acid (DNA and RNA) molecule markers comprise APM1 (+45), CDKAL1 (rs10946398), TCF7L2 (rs7903146) , CDKN2A / 2B (rs10811661), KCNQ1 (rs2237892), VDR (FokI) and SLC30A8 (rs13266634). The kit comprises: specific amplification primer pairs and DNA sequencing primer pairs of the gene polymorphism loci, PCR reaction liquids, PCR product enzymolysis liquids and DNA sequencing reaction liquids. According to the present invention, detection is performed by using the kit, gene information is processed and analyzed, diabetes type II susceptivity of a healthy subject is evaluated, and guiding significance is provided for personalized treatment and health care of diabetes type II people.

The invention relates to a cardia adenocarcinoma auxiliary diagnosis kit related to a group of genes, belongs to the technical field of biomedicine and molecular biology, and particularly relates to an ELISA kit for auxiliary diagnosis of cardia adenocarcinoma. The kit comprises a solid phase carrier and six antibodies which are respectively coated on the solid phase carrier, wherein the six antibodies are as follows: BCL2L1 antibody, DLC1 antibody, CDKN2A antibody, CDKN2B antibody, NRG1 antibody, ErbB4 antibody. Experiments prove that the group of related gene expression product has high expression in the serum of a cardia adenocarcinoma patient, the expression level of the related gene in the human serum is detected by the ELISA kit, and the detection result can be used for auxiliary diagnosis of the cardia adenocarcinoma such as early-onset screening, prognosis evaluation and the like, and the ELISA kit for auxiliary diagnosis of cardia adenocarcinoma has profound clinical significance and important popularization and application prospect.

The invention provides a kit for predicting recurrence and transference risk of a patient suffering from early-stage operable esophageal squamous carcinoma. The kit contains amplification primers of 32 genes of BCL2, Survivin, STAT3, cIAP1, cIAP2, beta-catenin, Cyclin D1, CDKN2A, TCF4, EGFR, HER-2, AREG, EREG, TFPI-2, WNT1, BMI-1, MTOR, ATM, ATR, XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, HIF-1alpha, HIF-2alpha, VEGF, RAD51, beta-actin, GAPDH, GUS and TFRC in all. The kit is capable of accurately predicting transference potential of early-stage operable esophageal squamous carcinoma, so that the transference and recurrence risk of the patient suffering from the early-stage operable esophageal squamous carcinoma after radical operation can be accurately predicted and evaluated, patients with high risk can be particularly monitored and effectively interfered, recurrence and transference of esophageal squamous carcinoma can be reduced, and prognosis of the patients can be further improved.

The present disclosure relates to a method of treating cancer using a composition comprising Nelfinavir, Metformin, Rosuvastatin, optionally along with a pharmaceutically acceptable excipient. The said composition is used for the treatment of cancer caused due to aberration in PTEN gene, optionally along with aberration in TP53 gene and related genes selected from group comprising PI3K, CDKN2A, MDM2 and MDM4.

The invention discloses gene markers for forecasting an immunotherapy effect on a cancer and application of the gene markers. The markers comprise BRD4, RPS6KA4, TET1, BCL10, FGFR2, RAD51C, TCF7L2, TGFBR1, AR, BBC3, H3C11, TSC2, NSD1, PNRC1, IGF2, H3C3, SOCS1, TCF3, TSHR, PMS2, EGFR and CDKN2A. According to the application, a model constructed by 22 genes can be used for predicting an immunotherapy effect and better instructing clinical medication, and the susceptibility and specificity of prediction of the model are superior to those of PD-L1 expression.

The invention relates to the technical field of molecular diagnosis, in particular to a composition for detecting mutation of lung adenocarcinoma cell cycle progress pathway related genes (CDKN2A, CCND1, CCNE1, CDK4 and RB1) and application of the composition, and the composition is composed of reagents for detecting the expression quantity of the related genes. RNA sequencing, LASSO and binary classification Logistic regression are applied to screen genes related to the cell cycle progress pathway, a score Score is constructed, a cut-off value corresponding to the Score in the lung adenocarcinoma is obtained through ROC analysis, and the method can be used for predicting mutation of the lung adenocarcinoma cell cycle progress pathway related genes. The specific gene mutation of the lung adenocarcinoma is predicted by using the expression quantity of the gene composition, and verification shows that the prediction method has the advantages of high accuracy and good specificity, and has a good application prospect.

The invention relates to a CDKN2A epitope peptide for detecting cervical cancer markers and an application of the CDKN2A epitope peptide, and belongs to the technical field of biology. An amino acid sequence of the CDKN2A epitope peptide for detecting the cervical cancer markers is as shown in SEQ ID NO:1; and the CDKN2A epitope peptide for detecting the cervical cancer markers is applied to preparation of an early diagnosis kit for cervical cancer. The CDKN2A epitope peptide has the advantages that the autoantibody expression level in serum and plasma of a patient with the cervical cancer is detected and a corresponding reagent is developed; the dangerousness of the cervical cancer is predicted; and a foundation is laid for preparation of the early diagnosis kit for the cervical cancer.

The invention relates to the technical field of gene detection, and discloses a detection kit for oral squamous cell carcinoma lymph node metastasis prediction. The kit comprises forward primer and reverse primer sequences of 7 kinds of genes including PDGFRA, PLAU, SOX9, SPP1, CDKN2A, CASP1 and MAL. The invention also discloses a method for screening the gene or the gene combination for the oralsquamous cell carcinoma lymph node metastasis prediction. The detection kit can be used for objectively, accurately and sensitively predicting the oral squamous cell carcinoma lymph node metastasis condition, so that the survival rate of the oral squamous cell carcinoma patients can be favorably improved.

The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans.

The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also relates to a method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2), wherein said “SHP2 signature” genes consist of the genes SGCB, ZSCAN12, ID4, ZIC3, CPVL, HLA-A, MCOLN3, SPATA18, TMEM45A, GNAL, CYBRD1, TSPAN7, ZEB1, CNTLN, NEFL, CENPV, ARL6, HPRT1, LRRC34, PDPN, BEND7, SLC16A10, FAM27E1, PLEKHA1, HERC5, CHIC1, PHF6, ELOVL4, ANTXR1, PRAME, SCML1, CLIP4, CECR2, CNOT10, IGF2BP3, NAP1L3, GPC3, KIAA1804, DGKE, FAS, EPHA6, KDELC1, CRISPLD1, DOCK3, ACSL4, CNTNAP3, PLEKHM3, RDX, TBX18, RRAGD, HOXB5, SNCA, FUNDC2, ITGA8, HFM1, IGF2BP2, CCND2, SGTB, MKX, CRYBG3, WBP5, LPHN3, BEX4, CPNE8, GLDC, SLC35F1, HOXA13, SERPINF1, NEFM, SYCP2L, FHL1, APOBEC3C, CALD1, FKBP10, HOXD11, DENND2C, LRRC49, FAM55C, KIAA0408, HOXB9, C160RF62, ACN9, TUSC3, ELOVL2, SPOCK3, HOXB6, WDR35, MPP1, FBX038, PRKAA2, SLAIN1, NPHP3, KIAA1524, PRPS1, GJC1, AMOT, SLC9A6, KCTD12, NUP62CL, DZIP3, JAM3, HOXA9, ANKRD19, CDKN2A, BCAT1, OAT, LPHN2, CCDC82, HSD17B11, SAMHD1, WDR17, STK33, GSTP1, TRPC1, CKB, LIN28B, ALDH1L2, SACS, CLGN, MY03A, EPB41L3, SLC25A27, VCAN, GPX8, GALNT13, PVRL3, MOXD1, HEY1, MAP7D3, ESD, MPP6, EYA4, SPG20, ZDBF2, ZNF204, IFT57, AKR1B1, ADAT2, ZNF717, CCDC88A, ZNF215, MIDI, FBN2, LOC100130876, TCEAL8, IGF2BP1, ANKRD18B, PLAGL1, PM20D2, LDHB, C150RF51, PTPN11, EPB41L2, TLE4, GOLM1, C60RF192, HOXD13, SLIT2, UCHL1, DYNC2H1, CPS1, GPR180, PYGL, NRN1, PRTFDC1, SLC16A1, DSC3, TMC01, LRCH2, SLC6A15, DZIP1, HOXA5, HSPA4L, CDR1, PLS3, ECHDC1, SMARCA1, CXORF57, HOXD10, and IRS4.

Methods are disclosed herein for assaying a biological sample or a bodily fluid obtained from a subject by isolating, obtaining or using a microvesicle fraction from the biological sample or bodily fluid and detecting in the microvesicle fraction the presence or absence of a genetic aberration in an IDH1, TDH2, TP53, PTEN, CDKN2A, NF1, EGFR, RB1, PIK3CA, or BRAF gene. The methods may be used for aiding the diagnosis, prognosis, monitoring, or therapy selection in relation to a disease or other medical condition (e.g., a glioma) in a subject.

Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.

Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.

The present invention discloses a universal polypeptide vaccine. The universal polypeptide vaccine comprises at least one of the following 6 mutations: KRAS-G12R, KRAS-G12V, CDKN2A-H83Y, KRAS-Q61H, TP53-R248W and CDKN2A-P94L. Specifically, the universal polypeptide vaccine comprises at least one of the 6 mutations. The universal polypeptide vaccine can be used for preparing drugs for treating / preventing cancers (pancreatic cancers). The universal polypeptide vaccine has relatively good immunotherapeutic effects on the pancreatic cancers.

The present disclosure relates to a method of treating cancer using a composition comprising Nelfinavir, Metformin, Rosuvastatin, optionally along with a pharmaceutically acceptable excipient. The said composition is used for the treatment of cancer caused due to aberration in PTEN gene, optionally along with aberration in TP53 gene and related genes selected from group comprising PI3K, CDKN2A, MDM2 and MDM4.

The invention relates to molecular biology, in particular to a mutation site combination and a primer for detecting susceptible genes of type 2 diabetes as well as an application of the combination and the primer. The mutation site combination comprises 21 mutation sites from KCNQ1, C2CD4A, TCF7L2, SLC30A8, CDKAL1, CDKN2A / 2B, KCNJ11, PPAR2, IGF2BP2, FTO, JAZF1, GRK5, RASGRP1, HHEX, PTPRD and SSR genes. Experimental research finds that the selected mutation site combination can effectively judge whether the sample is type 2 diabetes when used for detecting mutation site genes. The best detection combination is screened out from 21 SNP sites disclosed in the prior art, and the detection accuracy rate is increased to 92% or above on the basis of cost control.

The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer.

The invention discloses lung cancer targeted drug and chemotherapy drug genomes and an application thereof in lung cancer clinical drug treatment. The targeted drug genome comprises AKT1, ALK, BRAF, CCND1, CDKN2A, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, IGF1R, KDR, KIT, KRAS, MAP2K1, MET, NF1, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RET, ROS1, STK11 and TP53; and the chemotherapy drug genome comprises ABCB1, CDA, CEP72, CYP1B1, CYP2C8, DPYD, ERCC1, ERCC2, GSTM, GSTP1, MTHFR, RRM1, SLCO1B1, TEKT4, TPMT, TYMS, UMPS, XPC and XRCC1. The lung cancer targeted drug and chemotherapy drug genomes disclosed by the invention are applied to guidance of clinical precise chemotherapy of the lung cancer or auxiliary diagnosis of the lung cancer and curative effect and after-healingmonitoring, can provide the most effective drug selection for lung cancer patients with drug resistance or toxic and side effect intolerance caused by conventional drugs and targeted and chemotherapydrug requirements, improve the drug treatment effect, and reduce the toxic and side effects of the drugs.

The invention relates to a cardia adenocarcinoma auxiliary diagnosis kit related to a group of genes, belongs to the technical field of biomedicine and molecular biology, and particularly relates to an ELISA kit for auxiliary diagnosis of cardia adenocarcinoma. The kit comprises a solid phase carrier and six antibodies which are respectively coated on the solid phase carrier, wherein the six antibodies are as follows: BCL2L1 antibody, DLC1 antibody, CDKN2A antibody, CDKN2B antibody, NRG1 antibody, ErbB4 antibody. Experiments prove that the group of related gene expression product has high expression in the serum of a cardia adenocarcinoma patient, the expression level of the related gene in the human serum is detected by the ELISA kit, and the detection result can be used for auxiliary diagnosis of the cardia adenocarcinoma such as early-onset screening, prognosis evaluation and the like, and the ELISA kit for auxiliary diagnosis of cardia adenocarcinoma has profound clinical significance and important popularization and application prospect.

The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising measuring m RNA expression levels of at least MDM2, preferably of a four gene panel comprising MDM2, XPC, BBC3 and CDKN2A, as a biomarker for predicting the response.

The invention provides a target genome for gene detection of a non-small cell lung cancer patient and a related evaluation method, application and kit. The target genome is used for evaluating whetherthe non-small cell lung cancer patient has the necessity of tumor mutation load detection or not, and the target genome comprises the following genes of EGFR, TP53, CDKN2A and SDHA.

The invention discloses a universal polypeptide vaccine, which contains at least one of the following six mutations: KRAS-G12R, KRAS-G12V, CDKN2A-H83Y, KRAS-Q61H, TP53-R248W, CDKN2A-P94L. Specifically: at least one of the polypeptide sequences for the six mutations is included. The universal polypeptide vaccine can be used to prepare medicine for treating / preventing cancer (pancreatic cancer). The universal polypeptide vaccine of the invention has better immunotherapy effect on pancreatic cancer.

The invention relates to a marker and a model for predicting chemotherapy response of triple negative breast cancer. The marker comprises one or a combination of more than two of the following genes: AKT2, ARG1, BIRC7, CCR3, CDKN2A, CHGB, CNN1, CYP7A1, FGF5, KMT2A, NME1, NRAS, PCP4, PRC1, PRKCI, SUZ12, VEGFC, WRN and ZBTB16. According to the method, the chemotherapy response is taken as a target function, and the accurate model for predicting the chemotherapy response of the triple-negative breast cancer is established by utilizing the whole transcriptome data of the triple-negative breast cancer slice based on an iterative linear regression algorithm of correlation coefficient layering. By utilizing the model, evaluation can be performed before chemotherapy of a triple-negative breast cancer patient, and the model is used for guiding establishment of a treatment scheme.

The invention relates to a CDKN2A epitope peptide for detecting cervical cancer markers and an application of the CDKN2A epitope peptide, and belongs to the technical field of biology. An amino acid sequence of the CDKN2A epitope peptide for detecting the cervical cancer markers is as shown in SEQ ID NO:1; and the CDKN2A epitope peptide for detecting the cervical cancer markers is applied to preparation of an early diagnosis kit for cervical cancer. The CDKN2A epitope peptide has the advantages that the autoantibody expression level in serum and plasma of a patient with the cervical cancer is detected and a corresponding reagent is developed; the dangerousness of the cervical cancer is predicted; and a foundation is laid for preparation of the early diagnosis kit for the cervical cancer.